Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, taking place in Barcelona from 11-14 March.

New data show that wearable neuromodulation can be used with CGMs without disrupting glucose accuracy or connectivity.

Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026.

(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more ...

BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.